Premium
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal
Author(s) -
LIESENFELD K.H.,
LEHR T.,
DANSIRIKUL C.,
REILLY P. A.,
CONNOLLY S. J.,
EZEKOWITZ M. D.,
YUSUF S.,
WALLENTIN L.,
HAERTTER S.,
STAAB A.
Publication year - 2012
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2011.04609.x
Subject(s) - dabigatran , medicine , atrial fibrillation , rebuttal , direct thrombin inhibitor , cardiology , bioequivalence , population pharmacokinetics , population , pharmacokinetics , anesthesia , warfarin , environmental health , political science , law
See also Liesenfled K‐H, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, EzekowitzMD, Yusuf S,Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial. J Thromb Haemost 2011; 9: 2168–75; and Patel JP, Green B, Patel RK, Davies JG, Arya R. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: a rebuttal. This issue, pp 500–2.